Compare Summit Therapeutics Inc (SMMT) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Invesco S&P 500 Momentum ETF — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Invesco S&P 500 Momentum ETF trades at $151.06. The key difference: Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | SPMO | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $26.98 | $161.66 |
52-Week Low | $12.55 | $107.84 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
SPMO is trading at $151.21, up 1.69% with strong momentum characteristics. The ETF has demonstrated significant outperformance versus the S&P 500, gaining 26% year-to-date according to 24/7 Wall Street (2026-07-20). Technical indicators show a bullish trend with support at $147-148 and resistance at $149-151, though RSI levels suggest potential near-term consolidation.
The momentum-focused strategy continues to deliver alpha through concentrated technology exposure, particularly AI beneficiaries. However, high concentration risk and sector rotation vulnerability present challenges. With institutional interest growing and momentum factor dominance persisting, SPMO offers strategic exposure to market leaders but requires monitoring for momentum shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
